Lignes directrices de pratique clinique 2008 de l - Canadian ...

genital malformations after first-trimester exposure to ACE
inhibitors. N Engl J Med. 2006;354:2443-2451.
66. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target
for renoprotection in patients with type 2 diabetic nephropathy:
lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
67. de Zeeuw D, Remuzzi G, Parving HH, et al. Albuminuria, a therapeutic
target for cardiovascular protection in type 2 diabetic
patients with nephropathy. Circulation. 2004;110:921-927.
68. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing
end-stage renal disease in patients with type 2 diabetes and nephropathy:
the RENAAL study. Kidney Int. 2003;63:1499-1507.
69. Forsblom CM, Groop PH, Ekstrand A, et al. Predictive value of
microalbuminuria in patients with insulin-dependent diabetes
of long duration. BMJ. 1992;305:1051-1053.
70. Zoja C, Benigni A, Remuzzi G. Cellular responses to protein
overload: key event in renal disease progression. Curr Opin
Nephrol Hypertens. 2004;13:31-37.
71. The Diabetes Control and Complications (DCCT) Research
Group. Effect of intensive therapy on the development and progression
of diabetic nephropathy in the Diabetes Control and
Complications Trial. Kidney Int. 1995;47:1703-1720.
72. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose
control with sulphonylureas or insulin compared with
conventional treatment and risk of complications in patients
with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
73. Viberti G, Wheeldon NM; MicroAlbuminuria Reduction With
VALsartan (MARVAL) Study Investigators. Microalbuminuria
reduction with valsartan in patients with type 2 diabetes mellitus:
a blood pressure-independent effect. Circulation. 2002;106:
672-678.
| S147
CompliCations et troubles Comorbides